alexa Potential Benefits Of Roflumilast In Bronchial Asthma
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

9th Annual European Pharma Congress
June 26-28, 2017 Madrid, Spain

Hussam Murad
Department of Pharmacology, Faculty of Medicine, Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia
Department of Pharmacology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Keynote: Pharmaceut Reg Affairs
DOI: 10.4172/2167-7689-C1-023
Abstract
Statement of the Problem: Bronchial asthma affects about 150 million people all over the world. The inflammatory mediators released from eosinophils, T-helper 2 lymphocytes, airway epithelium, and airway smooth muscle contribute to chronic inflammation and remodeling. Airway remodeling leads to progressive decline of lung functions and it is steroid resistant, thus there is a need for new medications with better anti-remodeling effect. Phosphodiesterase (PDE)-4 inhibitors have antiinflammatory and anti-remodeling properties. Roflumilast; a selective PDE-4 inhibitor; is approved as an add-on therapy for chronic obstructive pulmonary disease (COPD). The inflammation in COPD and severe asthma is neutrophilic while in asthma it is eosinophilic. Consequently, investigating effects of roflumilast in eosinophilic inflammation is beneficial. During exacerbation of murine acute asthma, roflumilast (oral and intratracheal) decreased airway macrophages, eosinophils, neutrophils, T-helper 2 cytokines, and hyperresponsiveness (AHR). In contrast, steroids failed to affect AHR or neutrophil numbers which are considered important parameters for exacerbations of human asthma. Addition of roflumilast to high-dose fluticasone in patients with uncontrolled asthma improved asthma possibly through affecting the neutrophilic component of the disease. Ability of roflumilast to reduce sputum eosinophils, neutrophils, and macrophages makes it of potential off-label use in asthma. In a lipopolysaccharide-induced inflammation model in Wistar rats, "inhaled" roflumilast N-oxide decreased neutrophils in the bronchoalveolar lavage fluid (BALF). Thus "inhaled" roflumilast N-oxide could be as a useful alternative to oral roflumilast in airway disorders. Conclusion & Significance: Roflumilast (oral or inhalational) significantly decreases airway hyperresponsiveness, the elevated inflammatory mediators, the elevated BALF levels of matrix metalloproteinase-9 and its inhibitor (TIMP-1), and remodeling in both human asthma and animal asthma models. These benefits are due to its anti-inflammatory and anti-fibrotic effects. Investigating the effects of a triple inhalation therapy consisting of roflumilast, corticosteroids, and long acting β2 agonists in chronic asthma models is a point for research.
Biography

Hussam AS Murad worked as a Professor at Pharmacology and Clinical Pharmacy Departments in a number of universities in Egypt and Saudi Arabia. He has an experience of about 25 years in teaching and research. Murad has worked in 10 research projects as a principal investigator and as a first co-investigator in another four. He has got funds from King Abdulaziz City for Science and Technology (KACST), Riyad, SA, and Deanship of Scientific Research, King Abdulaziz University (KAU), Jeddah, SA. He received the award of scientific publication from KAU, in 2015 and in 2017.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords